2016 VAM: 1001 - Allergen Immunotherapy, Today and Tomorrow: Session I. Inhalant Allergens for Allergic Rhinitis and Asthma
The course will summarize state of the art of allergen immunotherapy for asthma and allergic rhinitis, including new observations on immunologic changes associated with immunotherapy, and will include a special emphasis on inducing tolerance to inhalant allergens.
AMA PRA Category 1 Credits™: 2.50
Credit must be claimed by May 31, 2018. Any credit request on or after June 1, 2018 will be subject to an administrative fee.
Allied Health Professionals
Upon completion of this activity, participants should be able to:
1. Discuss current and future approaches to allergen immunotherapy for asthma and allergic rhinitis
2. Discuss the potential mechanisms by which immunotherapy modulates the immune response to allergens
3. Discuss the durability of immune unresponsiveness induced by allergen immunotherapy
Relevant relationships: ALK-Abello (Ongoing): Consultant
Relevant relationships: None
Dr. Tolly Epstein, MD MS FAAAAI, University of Cincinnati Division of Immunology, Allergy, & Rheumatology, Cincinnati, OH Relevant relationships: None
Annual Meeting sessions and faculty were reviewed by members of the Practice Improvement Subcommittee. Disclosures are located in the 2016 Annual Meeting Disclosures PDF.
- 2.50 AttendanceAttendance credit.
- 2.50 CECE credit.
- 2.50 CMECME credit.